Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Bosentan Is Cost-Effective For Patients With Moderate PAH
Bosentan appears to be a more cost-effective initial treatment option for patients with moderate pulmonary arterial hypertension (PAH), classified as WHO functional class III, than no active intervention.
generic viagra online
Molecular Life Sciences New Online Publication
Cold Spring Harbor Laboratory Press has launched a new monthly publication, Cold Spring Harbor Perspectives in Biology, that provides comprehensive, systematically structured surveys of research in exciting areas of molecular and cellular biology, genetics, developmental biology, neuroscience, cancer biology, and molecular pathology.
News of the day
IOPHARM Presents Positive Indibulin Translational And Dose Scheduling Data At ASCO
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented positive data from both a Phase Ib clinical trial and preclinical dosing studies of orally administered indibulin (ZybulinTM or ZIO-301), the Company"s novel tubulin binding agent, at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.
Endocrinology

Radiotherapy Link To Breast Cancer And Heart Disease Found

Scientists have found a way to identify breast cancer patients at risk of heart disease after radiotherapy, according to a report published yesterday. Radiotherapy is commonly used to treat those patients who have had breast conservation surgery, and those who are at high risk of the cancer returning after mastectomy. When the breast tumour is on the left side, a small part of the heart is within the treatment range which can lead to heart disease. Dr Paul Symonds, of the University of Leicester"s Department of Cancer Studies and Molecular Medicine, studied 149 patients who had undergone radiotherapy for breast cancer. After treatment some patients developed red dilated blood vessels (telangiectasia) on the breast or chest wall, previously thought to be unsightly rather than of any medical significance. The findings, published in the British Journal of Cancer, revealed that only those who had radiotherapy on the left side developed heart problems, which occurred between three and 12 years after treatment. Over half of those who developed heart problems showed signs of telangiectasia. These figures are significant enough to suggest that telangiectasia could be a marker to predict the risk of heart disease after radiotherapy for breast cancer on the left side. Dr Symonds is now studying the genes of 1,000 patients who have undergone radiotherapy to try and identify those likely to experience side effects which could lead to heart disease. He said, "Ultimately this research could lead to a test to predict which patients will develop severe radiotherapy side-effects. Clinicians can then use this information to advise patients of their risk before treatment and help the radiotherapist give the most appropriate treatment." Pamela Goldberg, Chief Executive, Breast Cancer Campaign, which funded the study said, "More and more women are living with breast cancer as a long term manageable condition rather than an incurable disease. It is therefore vital that treatment not only improves the chance of survival but does not lead to other negative health consequences and maintains a good quality of life." Breast Cancer Campaign


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009